Literature DB >> 28499936

Umbilical Cord Blood Transplantation without Antithymocyte Globulin Results in Similar Survival but Better Quality of Life Compared with Unrelated Peripheral Blood Stem Cell Transplantation for the Treatment of Acute Leukemia-A Retrospective Study in China.

Juan Tong1, Li Xuan2, Yanling Sun3, Dongping Huang4, Huilan Liu1, Changcheng Zheng1, Xiaoyu Zhu1, Baolin Tang1, Kaidi Song1, Xuhan Zhang1, Lei Zhang1, Wen Yao1, Dongjun Lin3, Qifa Liu5, Zimin Sun6.   

Abstract

Although previous studies have demonstrated improved outcomes in umbilical cord blood transplantation (UCBT) by omitting antithymocyte globulin (ATG) in the conditioning regimen, this approach has not been comparatively studied in unrelated peripheral blood stem cell transplantation (UPBSCT). To compare the risks and benefits between UCBT without ATG and UPBSCT in patients with acute leukemia (AL), we conducted a multicenter retrospective study of 79 patients who underwent UCBT (myeloablative conditioning without ATG) and 96 patients who underwent UPBSCT (myeloablative conditioning with ATG). The outcomes were graft failure, neutrophil engraftment, platelet engraftment, acute graft-versus-host disease (aGVHD), chronic graft-versus-host disease (cGVHD), transplantation-related mortality (TRM), relapse, overall survival (OS), and leukemia-free survival (LFS). Follow-up was censored on October 31, 2016. Engraftment was similar between the 2 groups but granulocyte and platelet recovery were slower in the UCBT group (both P < .001). The incidences of aGVHD, TRM, OS, and LFS were similar between the 2 groups (all P > .05). Without ATG, the UCBT group displayed less cGVHD and less moderate and severe cGVHD (P < .001 and P = .004). The incidences of Epstein-Barr virus viremia and post-transplantation lymphoproliferative disease were significantly lower in the UCBT group (P < .001 and P = .037). UCBT recipients had higher activity Karnofsky performance scores and 3-year GVHD-free/relapse-free survival than the UPBSCT group (P = .03 and P = .04). We observed similar survival when comparing UCBT without ATG and UPBSCT, but we also observed better quality of life in patients undergoing UCBT without ATG. We can therefore conclude that patients with primary AL for whom an appropriate HLA-matched sibling donor is not available could select either UCBT or UPBSCT.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute leukemia; Antithymocyte globulin; Quality of life; Umbilical cord blood transplantation; Unrelated peripheral blood stem cell transplantation

Mesh:

Substances:

Year:  2017        PMID: 28499936     DOI: 10.1016/j.bbmt.2017.05.004

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  5 in total

Review 1.  Umbilical cord blood: an undervalued and underutilized resource in allogeneic hematopoietic stem cell transplant and novel cell therapy applications.

Authors:  Patricia A Shi; Larry L Luchsinger; John M Greally; Colleen S Delaney
Journal:  Curr Opin Hematol       Date:  2022-08-29       Impact factor: 3.218

Review 2.  Clinical Relevance of Immunobiology in Umbilical Cord Blood Transplantation.

Authors:  Hyun Don Yun; Ankur Varma; Mohammad J Hussain; Sunita Nathan; Claudio Brunstein
Journal:  J Clin Med       Date:  2019-11-14       Impact factor: 4.241

3.  Haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood in hematologic malignancy patients: A report of 80 cases.

Authors:  Cong Zeng; Yan Chen; Juan Hua; Yi Liu; Ting-Ting Cheng; Xia Ma; Xu Chen; Shi-Yu Wang; Ya-Jing Xu
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

4.  Effects of signaling pathway inhibitors on hematopoietic stem cells.

Authors:  Yuyu Jiang; Zhaofeng Xu; Na Ma; Lizhi Yin; Caiqin Hao; Jing Li
Journal:  Mol Med Rep       Date:  2020-11-12       Impact factor: 2.952

Review 5.  Umbilical cord blood transplantation: Still growing and improving.

Authors:  Xiaoyu Zhu; Baolin Tang; Zimin Sun
Journal:  Stem Cells Transl Med       Date:  2021-11       Impact factor: 6.940

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.